Northern Trust Corp Aveo Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$8.48 - $14.97 $99,597 - $175,822	11,745 Added 23.28%	62,186 $929,000
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $11,270 - $14,867	-1,705 Reduced 3.27%	50,441 $415,000
Q2 2022 Aug 12, 2022	SELL	$3.51 - $6.67 $4,917 - $9,344	-1,401 Reduced 2.62%	52,146 $342,000
Q1 2022 May 13, 2022	SELL	$3.15 - $6.01 $10,700 - $20,415	-3,397 Reduced 5.97%	53,547 $300,000
Q4 2021 Feb 08, 2022	SELL	$4.69 - $7.4 $10,491 - $16,553	-2,237 Reduced 3.78%	56,944 $267,000
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $16,322 - $21,965	3,188 Added 5.69%	59,181 $367,000
Q2 2021 Aug 13, 2021	SELL	$6.21 - $7.45 $1.07 Million - $1.29 Million	-172,793 Reduced 75.53%	55,993 $369,000
Q1 2021 May 12, 2021	SELL	$5.97 - $15.28 $83,896 - $214,729	-14,053 Reduced 5.79%	228,786 $1.68 Million
Q4 2020 Feb 11, 2021	BUY	$5.08 - $6.68 $73,507 - $96,659	14,470 Added 6.34%	242,839 $1.4 Million
Q3 2020 Nov 16, 2020	BUY	$4.16 - $6.26 $279,352 - $420,371	67,152 Added 41.65%	228,369 $1.36 Million
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $473,127 - $1.36 Million	136,348 Added 548.26%	161,217 $830,000
Q1 2020 May 14, 2020	BUY	$2.6 - $6.9 $64,659 - $171,596	24,869 New	24,869 $90,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.